Who are Fluorsalan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Codeine, Nalorphin, Ids-Ne-007, Revivon, OXYCONTIN®, OxyContin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flusalan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fluorsalan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluorsalan (flusalan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: flusalan. Area: Pain.

unknown flusalan Kappa-type opioid receptor, Mu-type opioid receptor Pain Live · refreshed every 30 min

Target snapshot

Fluorsalan (flusalan). Fluorsalan works by binding to and activating kappa-type opioid receptors in the brain, which can help reduce pain without the same risks as traditional opioids.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fluorsalan TARGET	flusalan		unknown	flusalan	Kappa-type opioid receptor, Mu-type opioid receptor
Codeine	codeine phosphate	Generic (multiple manufacturers)	marketed	Opioid analgesic, Antitussive	Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor	1950-01-01
Nalorphin	NALORPHINE		marketed	nalorphine	Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
Ids-Ne-007	ETORPHINE		marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
Revivon	DIPRENORPHINE		marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
OXYCONTIN®	OXYCONTIN®	Mundipharma (China) Pharmaceutical Co. Ltd	marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor
OxyContin	oxycodone	Purdue Pharma	marketed		Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-10-09 — OxyContin · 7771707 · Formulation · US
2030-12-10 — OxyContin · 9682075 · Formulation · US
2030-12-10 — OxyContin · 10004729 · Formulation · US
2030-12-10 — OxyContin · 10668060 · Formulation · US
2036-09-02 — OxyContin · 10188644 · Formulation · US
2036-09-02 — OxyContin · 9968598 · Formulation · US
2036-09-02 — OxyContin · 9737530 · Formulation · US
2036-09-02 — OxyContin · 10646485 · Formulation · US

Sponsor landscape (flusalan class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluorsalan — Competitive Intelligence Brief. https://druglandscape.com/ci/flusalan. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing